Hwanin Pharmaceutical (016580) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Hwanin Pharmaceutical is dated 2025-10-30; the most recent is 2025-10-30. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2025-10-30 | SELL | 증여 | 이광식 Gwangsik Lee | CEO Chairman | -1.9M | ₩11,340 | +0.4% | ₩21.1B ($14.6M) |
| 2025-10-30 | BUY | 수증 | 이원범 Wonbeom Lee | CEO and President | 1.9M | ₩11,340 | -0.4% | ₩21.1B ($14.6M) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Hwanin Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.